Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Virtual Preceptorship on Ovarian Cancer 2021

ESMO-Preceptorship-Virtual-Ovarian-2021-1000x250
Start date
06 Sep 2021
End date
07 Sep 2021
Location
Virtual, CEST Time

Learning objectives

  • To learn about best clinical practice in the multidisciplinary management of early and late stage ovarian cancer
  • To understand the importance of biology and pathology of common and rare ovarian tumours
  • To understand the options for treatment of recurrent disease and how treatment-decisions are made
  • To understand the novel therapeutic agents being developed to treat ovarian cancer and how knowledge of genomics and molecular pathways guides drug development
  • To learn about the management of patients with symptoms of the disease and the side-effects of treatment

Download the programme

Accreditation

The programme of this virtual event has been accredited with 7 ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to ESMO-MORA Recertification Process & Requirements.

Co-Chairs

  • Sandro Pignata, Italy
  • Isabelle Ray-Coquard, France

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.